RAC - Charts & Price Action, page-234

Yes COH are in the business of research. We have to remember that they didn’t set out to work with bisantrene, they tripped over it by chance screening through the 260,000 compounds in the NCI library.

I am sure they would like to see bisantrene get back into the clinic, the question is not when this will happen, but who will be leading this process.

COH have never said they are starting trials with bisantrene. They have been very careful in their statements to avoid saying if any trial will use bisantrene or brequinar. I am sure you guys can speculate on your own without my help about all this.